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Abstract: Cardiovascular disease remains the leading cause of death in Western society. Recent
technological advances have opened the opportunity of developing new and innovative smart stent
devices that have advanced electrical properties that can improve diagnosis and even treatment of
previously intractable conditions, such as central line access failure, atherosclerosis and reporting on
vascular grafts for renal dialysis. Here we review the latest advances in the field of cardiovascular
medical implants, providing a broad overview of the application of their use in the context of
cardiovascular disease rather than an in-depth analysis of the current state of the art. We cover their
powering, communication and the challenges faced in their fabrication. We focus specifically on
those devices required to maintain vascular access such as ones used to treat arterial disease, a major
source of heart attacks and strokes. We look forward to advances in these technologies in the future
and their implementation to improve the human condition.
Keywords: cardiovascular; atherosclerosis; implantable; smart; telemetry; communication; flexible;
sensor; reporting; lithography
1. Introduction
Implantable Medical Devices (IMDs) are in common use in medicine for diagnostic and
therapeutic purposes [1]. They cover a diverse set of pathologies including glucose monitoring
for diabetes, high blood pressure telemetry devices, cardiac reporters and defibrillators. Implantable
medical devices are diverse and can interact with physiological processes such as the heart beat and
mediate sensing and local stimulation, data recording and even drug delivery [2]. The latest IMDs can
transmit important measurements such as blood pressure, blood glucose level and electrocardiogram
from inside the body to the external world [3] many of these outputs can be used to aid clinical decision
making and offer a personalised medical approach to diagnosis and therapy, yet their implementation
faces significant challenges. Of particular interest is the potential of self-reporting cardiovascular
stents. These bare metal cages are used to reopen blocked vessels caused by “furring-up” of the
arteries. While this chronic disease is often fatal, patients “lucky” enough to be admitted to hospital
with chest pain will often undergo angiography in which radiopaque dye is delivered to the fine
coronary arteries of heart to detect narrowing’s that restrict blood flow and oxygen to the heart
muscle— the myocardium. While cardiac by-pass is an option where left internal mammary arteries
or saphenous veins taken from the legs are used as replacement conduit vessels, this is not a suitable
option for all patients. The alternative is balloon catheterisation and delivery of the stent via the femoral
arteries of the leg in which the device is threaded up to be deployed in the heart. Over 1 million
implantable medical cardiovascular stents are implanted per annum in the USA and another million in
Europe. The global market for medical devices is enormous and estimated conservatively at 8 Billion
Euros in 2017, growing at 10% per annum.
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Size, power and functionality constraints determine the design of an IMD and have limited their
use for vascular stents thus far [4]. Developments in biotechnology, microelectronics and material
science has now started to make it possible to overcome many of these constraints [5]. In recent years
there have been significant advances in low power miniaturization of devices with highly integrated
circuits (I.C.). Advances in microelectronics energy efficiency, ensuring long-life and improvements in
biocompatibility and communication protocols have allowed systems with real-time vital monitoring
to be implanted and to communicate wirelessly to report on chronic and acute medical conditions.
In this review we provide key examples of the types of devices currently used in clinical practice
and those more experimental that may eventually make it to market. While not possible to provide a
comprehensive in-depth analysis of all devices, we offer an overview of the types available that are
making a significant contribution to the clinical field. We explore the challenges in their methods of
fabrication and the integration of sensors onto these often-intricate designs.
We focus explore implantable medicals devices and their method of powering including passive
and wireless examples, compared to traditional charging and human energy harvesting systems.
Communicating with IMDs and the complexities of microfabrication are important for the future
success of these units. This area is investigated with examples of some of the latest techniques including
printable and stretchable electronics in the context of cardiovascular disease, such as implantable
blood pressure monitors in endovascular repair and coronary artery stents and leadless cardiac
resynchronization therapy.
2. Implantable Medical Devices
IMDs can be classified as either passive or active. A passive IMD is a medical device that
is not powered at all such as bare metal coronary artery stent [6]. An active IMD is “a medical
device that is equipped for its functioning with a source of electrical energy and is totally or partially
introduced, surgically or medically into the human body” [7]. The purpose of active IMDs is to
monitor physiological or pathological signals and/or to induce therapeutic effects by delivering
electric impulses to organs or tissues. In the case of coronary artery stents intimal hyperplasia (I.H.)
often termed restenosis or thickening of the inside of the vessel frequently occurs as a consequence of
delivery. This can occur in up to 15% of procedures despite the use of drug eluting stents that delivery
chemotherapeutic drugs to inactivate cell growth. Integrating active IMDs to either transmit the signals
they are monitoring to the external world and/or use it as input data for therapy is the “Holy Grail” of
cardiovascular stent research. The application of each type is dependent on the application proposed.
For example, cardiovascular stent technology would benefit from a passive device that doesn’t interfere
with the intrinsic electrical properties of the heart, whereas more power intensive applications such as
the blood pressure telemetry would benefit from a continuous high energy power supply.
3. Powering Implantable Medical Devices
While current cardiovascular stents are passive, requiring no electrical power, recent innovations
in smart devices provide examples of how power sources can be integrated to achieve interrogating
and transmitting effects to provide useful biological information. Smart devices often require a battery,
which in many instances occupies a significant portion of the space required by the device [1,2]. One of
the main advantages of battery powering is that it can provide a reliable continuous source of electrical
current [8].
For example the first implantable cardiac pacemaker in the late 1950s utilised zinc/mercury oxide
batteries [9] but are limited by their potential toxicity with the human body. Lithium/iodine became
the standard for implantable pulse generators by the mid-1980s. However, in recent years cardiac
pacemakers have become more sophisticated. They incorporate features such as memory to store
electrical activity of heart and telemetry. The power requirements have led to implementation of
lithium ion batteries with hybrid cathodes, which have higher power density. However, irrespective
of the innovations in battery technology, the lifetimes of batteries will always be limited and thus
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would require replacement by periodic surgical interventions [2]. Advances in microelectronics now
allow implants in the order of millimetres to be fabricated, but miniaturising the battery remains a
significant challenge. In the context of cardiovascular stents, wireless powering is a more realistic
long-term solution.
4. Wireless Powering
The battery size constraints makes wireless powering a very appealing possibility [10]. Instead of
batteries, electrical coils can be used to receive energy from another coil outside the body. Until recently
transferring energy beyond superficial depths in tissue required a coil of at least 1 cm in diameter.
If the implant is in the order of millimetres, then the coil was thought to become unpractical. Yet, recent
work by Ada Poon’s group at Stanford has developed high performance wireless powering systems
that could be integrated into minute medical devices such as stents. Using micrometer scale magnetic
resonance coupled radiofrequency identification (RFID) they have developed a series of wireless
biosensors that can be powered and relay signals from diverse orientations that may overcome this
previous limitation [10].
Some IMDs can be equipped with a rechargeable battery and a receiver coil [8]. A transmitter coil
outside the body generates a magnetic field which transfers energy through the skin to the receiver
coil. The magnetic field induces an alternating current (A.C.) in the receiver coil, and this is converted
to a direct current (D.C.) by a rectifier. This rectified voltage can be used to power the smart stent or
recharge the battery. A more elegant solution is using the body’s own waste energy for generating the
minimal power required for low power smart stent devices.
5. Human Energy Harvesting
Human energy harvesting is used to define systems that use the human body as primary energy
generator [11]. These systems capture gravitational, chemical, mechanical, thermal or electromagnetic
energy and convert it to electric energy [12]. The main issue is that the energy yield is quite low.
However, with the advent of ultralow power circuits, energy harvesting has become an attractive
solution to powering implants [13]. Tashiro et al. [14] developed a “variable-capacitance-type
electrostatic (VCES) generator that harnesses ventricular motion”. Its aim was to power a pacemaker
permanently without a battery. They used a variable capacitor which converts mechanical energy from
linear motion into electrical energy. The ventricular wall is chosen as the site of implantation because
it has a large motion which occurs continuously. Their system was capable of producing 36 µW for
powering a pacemaker for more than 2 h in an animal experiment. Clearly more work is needed
to achieve either greater power outputs for sustained, long-term indwelling devices or advances in
reducing power consumption of miniaturized devices thereby matching the needs of energy supply
with energy consumption.
6. Communicating with Implantable Medical Devices
When it comes to wireless active smart stents and IMDs, the trade-off is between power
consumption for high performance and power consumption for high data transmission rate [15]. This is
because the power which can be transmitted to the implant antenna is directly proportional to the size of
the latter. Moreover, regulations only allow transmission in the low-megahertz (MHz) frequency range,
thus leading to the low data transmission rates and the low power efficiency. Recent studies [10,16]
have shown that the power efficiency is optimal in the low-gigahertz frequency range, when using
these millimetre-sized antennas. Optimisation in energy transfer protocols and data processing such
as the use of fuzzy logic, neural networks and Bayesian interference through machine learning will all
help to minimise these artefacts.
For example an active smart stent would be made up of biosensors, a wireless module and a
miniaturised computer [17]. When the stent is implanted, it is configured according to the condition
of the patient. If at a later time point, the medical condition of the patient changes, the wireless
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module allows changes in configuration in order to optimise monitoring and/or treatment. The stent
can communicate with a remote server via a receiver [18]. The communication between stent and
receiver is achieved through Medical Implant Communication Service (MICS). The receiver then
communicates, via a wired network, with the server, which saves long term data. The possibilities
for the communication protocol between IMDs and/or wearable medical devices are as follows:
WLAN (wireless local area network), WPAN (wireless personal area network), LR-WPAN (low rate
wireless personal area network) and WBAN (wireless body area network) [18]. The first three are
more suitable for the on-body communication, while the latter is meant to be appropriate for the
in-body communication.
Hsu et al. [18] proposed a new scheme called E2R MedRadio employing the WBAN
communication protocol. The main objective of this scheme is to minimise energy consumption
of the IMD by increasing communication reliability. The IMD uses much of its internal power for
retransmission because of poor communication reliability. The latter can be enhanced by using group
communication. The patient has an electronic wrist-ring and/or patch which acts as wearable device(s).
In terms of communication protocol, the device is referred as IMD node, the wearable devices as
wearable nodes and the main server as header node. The wearable nodes relay information from
the IMD node to the header node. Thus, the IMD uses its energy for signal delivery only while the
wearable nodes process the signal and relay to main server. However, achieving these designs is reliant
on innovative fabrication techniques.
7. Microfabrication Techniques, Sensor Design
Microfabrication techniques which were first developed to produce integrated circuits have been
modified to create sensors for biomedical devices. Electronic and optoelectronic sensors range from
research devices that can electrically interface with brain tissue through densely packed microfabricated
needles [19] to therapeutic devices such as FDA(Food and Drug Administration) approved retinal
implants [20]. MicroElectroMechanical Systems (MEMS), defined as a semiconductor type device
where a mechanical part works together with an integrated circuit, are a further development of
microfabrication that then allows the detection of physical forces. This allows the creation of the
devices that include accelerometers, strain gauges, microphones, air mass flow sensors and pressure
sensors [21].
MEMS has allowed the manufacturing of smart medical devices small enough to be implanted in
the human body for health monitoring, sensing and therapy [22]. As MEMS technology progresses,
there will be further decreases in the size of the implants, which will also reduce invasiveness of
the procedures required for implantation. An example of where MEMS has enhanced an implant is
the cardiac resynchronisation therapy (CRT) device. It employs sensors for heart sounds in order to
optimise resynchronisation. When the sensors were miniaturised they could fit into the pacemaker
main body. Further miniaturisation allowed the sensor to be integrated into the tip of the leads in
direct contact with heart wall. Thus, the small size of the new sensor increased the reliability, as it was
in direct contact with organ requiring therapy.
The design and fabrication method is restricted by the material of choice [23] and for stents
these are often composed of chromium/platinum composites and memory nickel titanium alloys
such as nitinol. The latter satisfies the criteria of biocompatibility, hermeticity and mechanical
strength/durability. Successful in vitro experiments using biocompatible materials does not guarantee
successful operation following implantation, as the material can degrade with time and can also lead to
immune responses that drive inflammation and implant rejection. Materials used for fabricating
IMDs can be categorised as hard or soft. Other examples of hard biocompatible materials are,
cobalt-chromium, iridium and certain glasses, while examples of soft biocompatible materials are
poly(methyl methacrylate) (PMMA), polydimethylsiloxane (PDMS), Parylene C and polyimide and
even the dissolvable substrates such as Abbott Laboratories’ GT1 stent made from poly-L-lactic
acid (AbbottTM).
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Due to concerns about electrochemical corrosion and immune reactions, micro-machined sensors and
circuitry are enclosed within biocompatible materials [23]. Some of those materials also ensure hermeticity
and electrical insulation. Silicon remains the material of choice for micromachining applications because of
its compatibility with integrated circuitry (IC) and complementary metal–oxide–semiconductor (CMOS).
Glass is the material of choice in IMDs that incorporate wireless interrogation. This is because glass
provides electrical insulation of microfabricated metallic coils or antennae.
The sensor component(s) of a stent implant needs to be connected to an Application Specific
Integrated Circuit (ASIC) in order to transmit the recorded signal to the external world [24].
The ASIC comprises a microcontroller, signal conditioning circuits and radio communication circuitry.
Traditionally ASIC and sensors are assembled horizontally using Printed Circuit Boards (PCB). In order
to reduce footprint of the sensing system, vertical stacking can be used (Figure 1). This type of
convergent system is referred to as system-on-package (SOP) [25]. It incorporates system components
at microscale using thin-film technologies. It benefits from the synergy between the integrated circuit,
package and system. Tsai et al. [26] presented a micro-machined capacitive sensor with readout circuit
on a single chip. However, integrating useful electronics sensors and therapeutic circuitry with medical
devices is often limited by the traditional silicon materials used that have limited flexibility and are
intrinsically brittle.
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8. Printable and Stretchable Electronics
Stretchable interconnects, recently reviewed highlights advances made in overcoming the obstacle
of silicon based materials [27]. Nanocomposite based inks for printing using either dispersed carbon or
metal-based filler materials have become potential solutions. However, devices with large deformations
such as smart cardiovascular stents require stretchable portions, sophisticated safe harbour locations
for the non-flexible portions of the electronics or integrated silicon circuits to be protected. In essence,
these devices will require the synthesis of engineered shapes and rubber-like stretchable materials such
as polyurethane to achieve their goals of a personalised approach to medical devices. Integrating helical
or serpentine wavy shapes at the milli and microscale will also help achieve this. Sekitani et al. [28]
produced stretchable material using uniformly dispersed single walled carbon nanotubes (SWNTs).
Innovative printing techniques also offers alternatives to soft lithography. The dispersed solutions of
the conductors, dielectric and the semiconductor materials can be patterned onto the flexible substrates
directly with a high resolution of only a few cells thick (314–286 µm) [29].
Materials which can balance mechanical stretch ability with electrical conductivity could overcome
these issues of variable impedance for example. Polyaniline (PANi), poly(3,4-ethylenedioxythiophene):
poly(4-styrenesulfonate)(PEDOT:PSS) and ionic hydrogels made of PAM-Aam (LiCl) all offer significant
potential and have the advantage of being deformed up to 500% [30].
Sensors 2018, 18, 2008 6 of 11
9. IMDs in Cardiovascular Disease
Cardiovascular disease (CVD) is a major cause of death globally [31]. In 2013, CVD contributed
to 30% of global deaths or 17.5 million people. However, declines in population-based mortality
rates have been observed in many countries since 1970 [31]. This decline can be attributed to better
prevention of acute myocardial infarction and improved acute medical treatment. Thus, there is an
increasing number of patients living with chronic CVD [32]. Over the last 20 years in United Kingdom
(UK) surgical operations and medical treatment of CVD have significantly increased [33]. In 2012/2013,
the National Health Service (NHS) spent approximately £6.8 billion on CVD, mostly on secondary care.
The ageing UK population exerts the significant financial pressures on the current healthcare
system [34]. There is a need to reduce healthcare costs by minimizing inpatient hospital stays.
The implementation of more IMDs with communication capabilities into healthcare practice could
potentially relieve the strain on the health system. While smart cardiovascular stents could have the
most significant impact there are precedents for IMDs that can transmit data to the external world,
allowing caregivers to remotely access information about the physiological conditions of their patients
and decide whether further medical or surgical intervention is required. Some of these have already
reached regulatory approval [34] and have started a shift in the healthcare system from managing
illness in hospitals to managing wellness outside through the very early detection and treatment of
diseases prior to appearance of symptoms.
Cardiovascular IMDs can be regarded as the most sophisticated IMDs to date, for example
defibrillators and pacemakers, are life-sustaining devices [35]. As these devices are implanted inside
the body, it gives some level of autonomy to the patients, as they do not need to be hospitalised
for long periods of time and can even be remotely monitored. Other devices such as implantable
pressure monitors or implantable blood glucose monitors allow early diagnosis of low/high blood
pressure or blood glucose respectively, allowing patients/caregivers to take action prior to appearance
of symptoms. Here we provide examples of how far the technology has come.
9.1. Implantable Blood Pressure Monitors in Endovascular Repair
Some of the first implantable cardiovascular devices were used to treat abdominal aortic aneurysm
(AAA). This is an age-related ballooning of the aorta, the main arterial vessel of the body. The vessel
thins and becomes liable to rupture with often fatal consequences. The use of Endovascular Repair
(EVAR) for treating AAA repair was first approved by the FDA in 1999 [36]. It is a stent-graft synthetic
vascular mesh replacement and is used to exclude the aneurysm sac from systemic pressure. However,
the major complication of EVAR is endoleak, which is recurrent high pressure within the aneurysm sac.
It is very difficult to diagnose endoleaks using conventional imaging techniques, and thus measurement
of sac pressure is carried out using an angiographic catheter [37]. However, this catheter cannot be
kept inside the body for the long periods of time, and thus does not allow the long-term surveillance.
The EndoSure sensor (CardioMEMS, Abbott Laboratories, Atlanta, GA. USA) (Figure 2) is a
battery-less pressure sensing implant, which is deployed within the aneurysm sac and it is kept in
place using the wire basket that surrounds it [37]. It is a passive IMD since it does not include
any electronic components. It is simply an LC tank (inductive-capacitive tank). The inductive
component is fixed, while the capacitive component consists of flexible plates whose separation
varies with blood pressure [36]. As a result of the change in capacitance the resonant frequency
(while transmitting radiofrequency) changes. The shifts in resonant frequency is transduced into
real-time pressure measurements.
The Pulmonary Artery Pressure by Implantable device Responding to Ultrasonic Signal (PAPIRUS
II) study [38] tested the feasibility of using the ImPressure device (Boston Scientific, Marlborough,
MA, USA) for home monitoring of chronic heart failure (CHF). The device consists of an implant and
an external unit. The implant comprises a pressure sensor, a piezoelectric transducer, a control chip
and a battery (Figure 3). Ultrasonic energy is used to transmit a signal to the implant, activating its
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battery. The sensor measures full pressure waveforms for 10 s and the chip transmits the data to the
external unit. The ImPressure device is fixed to the outside of the endograft by hand-sewing [36].Sensors 2018, 18, x 7 of 11 
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latest stents have led o a different complication such as a apposition where the stent fails to contour
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low [43]. Clinically it is impossible to know what the stent is doing inside the v ssel hence alternativ
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thus works as a passive IMD. The stent (inductor) and sensor (capacitor) combination is inductively
coupled to an external coil, and the phase-dip is measured. Schachtele [44] modified this approach
by integrating two pressure sensitive transponders at either ends of the stent. The delay between
resonances of the two transponders is used to calculate the local pulse wave velocity. Son et al. [50]
developed a stent with electronic components, which thus functioned as an active IMD. In addition to
providing mechanical support, the smart stent had diagnostic and therapeutic capabilities. The stent
and all the added components were fully bioresorbable. The stent integrated a blood flow sensor,
a temperature sensor and an antiproliferative drug stored in a nanoparticle shell. The release of the
drug was controlled photothermally.
Integrating electronic components onto a stent is a major challenge because these components
need to resist stent crimping procedures and stent expansion [54]. Moreover, since the stent remains
inside the patient’s artery for the rest of his/her life, the stent with electronic components needs to
resist chemical and biological reactions. Chen et al. [54] developed a smart stent compatible with
routine crimping and deployment procedures. A pressure sensor was securely integrated onto the
stent using laser-microwelding. To ensure biocompatibility and X-ray opacity, Parylene C and gold
coatings were applied. The device was demonstrated to successfully monitor in-stent blood pressure
in a swine model.
9.3. Leadless Cardiac Resynchronisation Therapy
Conventional cardiac resynchronisation therapy involves the insertion of a transvenous lead,
which runs from the pacemaker to the pacing site [55]. The major complication with this approach is
lead failure, which occurs in 21% of patients within 10 years after implantation [56]. Other complications
include the infection, tricuspid valve insufficiency and central vein obstruction [57]. The possibility of
implementing leadless pacing has been considered for many years and has been shown to be feasible [58].
Leadless pacing can be achieved in two main ways [57]: (i) multicomponent devices, which consist
of a subcutaneous energy transmitter and an endocardial pacing electrode; (ii) self-contained devices,
which consist of a pacing electrode and pulse generator.
In the multicomponent design, energy needs to be transferred wirelessly from the transmitter to
the receiver unit. This can be achieved via ultrasound-mediated energy transfer or electromagnetic
induction. The Wireless Chronic Stimulation-Left Ventricle (WiCS-LV) system utilizes the acoustic
energy [59]. It is co-implanted with a CRT device, ICD (implantable cardioverter defibrillator) device
or pacemaker, and allows bi-ventricular pacing.
WiCS-LV detects the right ventricular pacing signal from the co-implanted device. The pulse
generator then generates ultrasonic energy. This is received by the receiver unit (implanted in left
ventricle), which converts the ultrasonic energy into an electrical pulse. Thus, the system allows
synchronous right and left ventricular pacing. The energy transfer to the receiver unit is optimised by
using beam-forming.
Wieneke et al. have shown that the energy transfer can also be achieved using electromagnetic
induction [58]. The subcutaneous transmitter unit consists of a coil which sends an alternating magnetic
field. This transmitter unit induces a voltage in the receiver unit which consists of a coil with a ferrite
core, a bridge rectifier and a high impedance lead tip. Electromagnetic resonance coupling allows
optimisation of the energy transfer. However, the energy transfer efficiency is affected by movement of
the receiver unit due to beating of the heart.
10. Discussion
The global population is continuing to live longer with more complicated medical conditions
with multiple co-morbidities. The associated care costs and increasing susceptibility to chronic
diseases will ensure the need for new and innovative devices with advanced medical diagnostic
and therapeutic properties. Interdisciplinary research continues to push the boundaries of what is
possible and develops high tech devices which integrate advanced sensor design, fabrication and
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manufacturing techniques. Those devices that make it to market will transform healthcare as we know
it and will have broad appeal across healthcare disciplines from cardiovascular to neurological and
renal pathologies. They will offer a personalised and stratified approach to medicine and will shift the
healthcare paradigm from purely diagnostic to therapeutic. With the collection of large datasets to
validate their use there is the opportunity for these devices to start a revolution in preventive medicine.
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